243 related articles for article (PubMed ID: 24421886)
21. Live attenuated Bordetella pertussis vaccine candidate BPZE1 transiently protects against lethal pneumococcal disease in mice.
Belcher T; Kammoun H; Coutte L; Debrie AS; Mielcarek N; Sirard JC; Cauchi S; Locht C
Vaccine; 2022 Mar; 40(11):1555-1562. PubMed ID: 33509692
[TBL] [Abstract][Full Text] [Related]
22. Non-specific Effects of Live Attenuated Pertussis Vaccine Against Heterologous Infectious and Inflammatory Diseases.
Cauchi S; Locht C
Front Immunol; 2018; 9():2872. PubMed ID: 30581436
[No Abstract] [Full Text] [Related]
23. Attenuated Bordetella pertussis BPZE1 protects against allergic airway inflammation and contact dermatitis in mouse models.
Li R; Cheng C; Chong SZ; Lim AR; Goh YF; Locht C; Kemeny DM; Angeli V; Wong WS; Alonso S
Allergy; 2012 Oct; 67(10):1250-8. PubMed ID: 22909095
[TBL] [Abstract][Full Text] [Related]
24. Construction and evaluation of a pertactin-deficient live attenuated pertussis vaccine candidate BPZE1 derivative.
Solans L; Debrie AS; Coutte L; Locht C
Vaccine; 2021 May; 39(21):2843-2849. PubMed ID: 33896662
[TBL] [Abstract][Full Text] [Related]
25. Live pertussis vaccines: will they protect against carriage and spread of pertussis?
Locht C
Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S96-S102. PubMed ID: 28341014
[TBL] [Abstract][Full Text] [Related]
26. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1.
Feunou PF; Ismaili J; Debrie AS; Huot L; Hot D; Raze D; Lemoine Y; Locht C
Vaccine; 2008 Oct; 26(45):5722-7. PubMed ID: 18762220
[TBL] [Abstract][Full Text] [Related]
27. Pertussis: Where did we go wrong and what can we do about it?
Locht C
J Infect; 2016 Jul; 72 Suppl():S34-40. PubMed ID: 27161992
[TBL] [Abstract][Full Text] [Related]
28. Will we have new pertussis vaccines?
Locht C
Vaccine; 2018 Aug; 36(36):5460-5469. PubMed ID: 29180031
[TBL] [Abstract][Full Text] [Related]
29. Dual mechanism of protection by live attenuated Bordetella pertussis BPZE1 against Bordetella bronchiseptica in mice.
Kammoun H; Feunou PF; Foligne B; Debrie AS; Raze D; Mielcarek N; Locht C
Vaccine; 2012 Aug; 30(40):5864-70. PubMed ID: 22814407
[TBL] [Abstract][Full Text] [Related]
30. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
[TBL] [Abstract][Full Text] [Related]
31. Attenuated Bordetella pertussis: new live vaccines for intranasal immunisation.
Mielcarek N; Debrie AS; Raze D; Quatannens J; Engle J; Goldman WE; Locht C
Vaccine; 2006 Apr; 24 Suppl 2():S2-54-5. PubMed ID: 16823926
[TBL] [Abstract][Full Text] [Related]
32. The Role of Mucosal Immunity in Pertussis.
Solans L; Locht C
Front Immunol; 2018; 9():3068. PubMed ID: 30692990
[TBL] [Abstract][Full Text] [Related]
33. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
[TBL] [Abstract][Full Text] [Related]
34. Construction and preliminary immunobiological characterization of a novel, non-reverting, intranasal live attenuated whooping cough vaccine candidate.
Cornford-Nairns R; Daggard G; Mukkur T
J Microbiol Biotechnol; 2012 Jun; 22(6):856-65. PubMed ID: 22573165
[TBL] [Abstract][Full Text] [Related]
35. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
Gustafsson L; Hallander HO; Olin P; Reizenstein E; Storsaeter J
N Engl J Med; 1996 Feb; 334(6):349-55. PubMed ID: 8538705
[TBL] [Abstract][Full Text] [Related]
36. Is there a need for a new generation of vaccines against pertussis?
Storsaeter J; Wolter J
Expert Opin Emerg Drugs; 2006 May; 11(2):195-205. PubMed ID: 16634696
[TBL] [Abstract][Full Text] [Related]
37. Attenuated Bordetella pertussis vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response.
Fedele G; Bianco M; Debrie AS; Locht C; Ausiello CM
J Immunol; 2011 May; 186(9):5388-96. PubMed ID: 21430219
[TBL] [Abstract][Full Text] [Related]
38. Live attenuated B. pertussis BPZE1 rescues the immune functions of Respiratory Syncytial virus infected human dendritic cells by promoting Th1/Th17 responses.
Schiavoni I; Fedele G; Quattrini A; Bianco M; Schnoeller C; Openshaw PJ; Locht C; Ausiello CM
PLoS One; 2014; 9(6):e100166. PubMed ID: 24967823
[TBL] [Abstract][Full Text] [Related]
39. Pertussis: acellular, whole-cell, new vaccines, what to choose?
Locht C
Expert Rev Vaccines; 2016 Jun; 15(6):671-3. PubMed ID: 26938372
[No Abstract] [Full Text] [Related]
40. Cross-species protection mediated by a Bordetella bronchiseptica strain lacking antigenic homologs present in acellular pertussis vaccines.
Sukumar N; Sloan GP; Conover MS; Love CF; Mattoo S; Kock ND; Deora R
Infect Immun; 2010 May; 78(5):2008-16. PubMed ID: 20176797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
